Silent suppression for Antisense
Wednesday, 15 October, 2008
Preclinical trials of Antisense Therapeutics’ [ASX: ANP] ATL1101 candidate have been shown to suppress human prostate tumour growth in animal models.
ATL1101 suppressed the growth of human tumours in mice that had been implanted with human prostate cancer sells.
The treatment slowed down the cancerous cells' transition to the most dangerous form of prostate cancer, castration-resistant prostate cancer [CRPC].
The study was conducted with the assistance of Martin Gleave, the director of the Prostate Centre at Vancouver General Hospital.
This is the first known demonstration of the efficacy of RNA-silencing IGF-I receptor drugs in prostate cancer models.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
